Drug firm Cadila Healthcare Monday said it has received establishment inspection report from the US health regulator with voluntary action indicated (VAI) classification for its Ahmedabad SEZ facility.
The United States Food and Drug Administration (USFDA) had conducted an inspection of the company's formulations manufacturing facility located at SEZ, Ahmedabad from March 25 to April 3, 2019, Cadila Healthcare said in a BSE filing.
The plant has received an establishment inspection report (EIR). The EIR report stated that the classification of the facility is VAI, it added.
As per the USFDA, VAI means that though "objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action".
Shares of Cadila Healthcare were trading at Rs 244.65 per scrip in the afternoon trade on BSE, down 0.26 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app